Evaluating the De-Escalation of Surveillance for Patients Who Have Undergone Curative Treatment for Breast Cancer (De-Escalation)
2026年4月30日 更新者：Royal College of Surgeons, Ireland
Evaluating the De-Escalation of Surveillance for Patients Who Have Undergone Curative Treatment for Primary Breast Cancer - A Prospective, Randomised Controlled Trial
Patients who were diagnosed with breast cancer and have finished their treatment will be given the opportunity to be part of this study.
These patients will have been attending surveillance at the Breast Centre in Beaumont Hospital, Ireland for 2 years prior.
These patients, who are doing well after breast cancer treatment, will be given the opportunity to enrol in this study, potentially being discharged from in person surveillance after 2 years, while still attending for their annual mammogram.
Investigators intend to find out if a simpler follow-up plan could work just as safely, while also improving the patients quality of life.
調査の概要
詳細な説明
Breast cancer is the most common cancer in women around the world. That means a lot of women are affected by it every year, and it's important that investigators always look for ways to improve their care, not just during treatment, but afterwards too. After treatment for early-stage breast cancer, patients usually come back to the hospital for regular check-ups for up to five years. These visits are based on old guidelines, and even though breast cancer treatment has improved a lot over the years, the follow-up schedule has stayed the same. This study is being done to see if investigators can safely reduce the number of hospital visits after treatment, while still keeping patients healthy and well looked after.
Right now, in Ireland, patients are asked to attend follow-up appointments at 6, 12, 18, 24, 36, 48 and 60 months (that's every 6 to 12 months for five years). These clinic visits often involve long waits and can cause stress or anxiety. At the same time, patients are also invited for a mammogram once a year. Recent research shows that most recurrences of breast cancer are found by patients themselves or during their annual mammograms, not necessarily at these clinic visits. That is why investigators are looking at whether the number of hospital appointments can safely be reduced , without affecting patient safety.
In this study, some patients will continue with the usual five-year clinic schedule. Others will only attend hospital clinics for the first two years (at 6, 12, 18 and 24 months), and after that, they will no longer need to come in for the extra follow-up visits - but they will still have their annual mammograms as normal.
Investigators will also ask all participants to complete a short questionnaire once a year. This will help investigators understand how the different follow-up plans affect quality of life, and how patients feel about their care. This research study is taking place to find out if fewer hospital check-ups, combined with continued mammogram screening, is just as safe and possibly better for patients' wellbeing.
研究の種類
観察的
入学 (推定)
560
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前：Emma Forde, Medical Doctor & Scientist
- 電話番号：+353896126509
- メール：eforde@rcsi.com
研究場所
-
-
-
Dublin、アイルランド、D09Y177
- 募集
- Beaumont Hospital
-
コンタクト：
- Emma E Forde, Licensed doctor
- 電話番号：+353 018092060
- メール：eforde@rcsi.ie
-
コンタクト：
- Professor ADK Hill, Professor and Chairman of Surgery
- 電話番号：+353 018092060
- メール：ADKHILL@rcsi.ie
-
主任研究者：
- Arnold DK Hill, Professor of Surgery
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
サンプリング方法
確率サンプル
調査対象母集団
Female patients, 18 years or older with a previous diagnosis of primary breast cancer who have completed two years of surveillance following curative treatment
説明
Inclusion Criteria:
- Female participants aged 18 years or older
- Prior diagnosis of primary breast cancer treated with curative intent
- Currently under cancer surveillance and at the 24-month follow-up timepoint
- No clinical or radiological evidence of disease recurrence or metastasis at the time of recruitment (e.g., no palpable mass, skin or nipple changes, or suspicious findings on imaging)
- Able to read, write, and speak English sufficiently to complete the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire (paper-based or via telephone)
- Resident in the Republic of Ireland with a fixed address and intention to continue follow-up within the Irish healthcare system
Exclusion Criteria:
- Evidence of breast cancer recurrence or metastatic disease at the time of recruitment
- Inability to provide informed consent
- Inability to complete study questionnaires (e.g., due to language barriers or cognitive impairment)
- Not resident in the Republic of Ireland or not intending to remain in follow-up within the Irish healthcare system
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Control
Patients will attend routine hospital-based in-person surveillance according to current practice post initial diagnosis (i.e.: patients will receive six monthly in-person specialist surveillance appointments for the first 24 months following curative resection and treatment of their primary breast cancer.
Thereafter, these patients will attend annually until five years surveillance is reached and they will then be discharged from the service).
Every patient will undergo an annual mammogram until the age of seventy years (or if aged 70 at the time of diagnosis, they will have an annual mammogram for five years in total).
All participants in this group will complete the health-related quality of life questionnaire, EQ5D5L at the 24 (2 year), 36 (3 year), 48 (4 year) and 60 month (5 year) timepoint
|
|
|
Intervention
Patients will attend hospital-based in-person specialist surveillance clinics according to the current practice post initial diagnosis for the first two years following curative resection and treatment of their primary breast cancer and then discharged from the service (i.e.: patients will receive six monthly specialist follow-up appointments for the first 24 months).
Mammographic surveillance will be as described for the control group.
Every patient will undergo an annual mammogram until the age of seventy years (or if aged 70 at the time of diagnosis, they will have an annual mammogram for five years in total).
As per standard practice all results from these annual mammogram studies will be copied to the patients' general practitioner.
If any abnormalities are detected on mammogram the patient will be contacted.
All participants will complete the health-related quality of life questionnaire, EQ5D5L at the 24 (2 year), 36 (3 year), 48 (4 year) and 50 month (5 year) timepoint
|
Patients will attend hospital-based in-person specialist surveillance clinics according to the current practice post initial diagnosis for the first two years following curative resection and treatment of their primary breast cancer and then discharged from the service (i.e.: patients will receive six monthly specialist follow-up appointments for the first 24 months).
Mammographic surveillance will be as described for the control group.
Every patient will undergo an annual mammogram until the age of seventy years (or if aged 70 at the time of diagnosis, they will have an annual mammogram for five years in total).
As per standard practice all results from these annual mammogram studies will be copied to the patients' general practitioner.
If any abnormalities are detected on mammogram the patient will be contacted.
All participants will complete the health-related quality of life questionnaire, EQ5D5L at the 24 (2 year), 36 (3 year), 48 (4 year) and 50 month (5 year) timepoint.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Health Related Quality of Life
時間枠：Participants will complete the questionnaire (paper-based or via telephone with the Advanced Nurse Practitioner) at 2, 3, 4, and 5 years.
|
Health related quality of life will be assessed using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L).
The EQ-5D-5L includes five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with five levels of severity.
Responses are converted into a single index value, typically ranging from less than 0 (worse than death) to 1 (full health), where higher scores indicate better health-related quality of life.
The instrument also includes a visual analogue scale (EQ VAS) ranging from 0 to 100, with higher scores indicating better perceived health.
|
Participants will complete the questionnaire (paper-based or via telephone with the Advanced Nurse Practitioner) at 2, 3, 4, and 5 years.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Recurrence Rate and Time to Recurrence
時間枠：Assessed at 2, 3, 4, and 5 years post enrollment, time to recurrence analyzed up to 5 years.
|
Recurrence rate will be defined as the proportion of participants diagnosed with disease recurrence during follow-up.
Time to recurrence will be defined as the time from study enrollment to the date of first confirmed recurrence.
|
Assessed at 2, 3, 4, and 5 years post enrollment, time to recurrence analyzed up to 5 years.
|
|
Change in Number of Patients Attending via Symptomatic Referral Pathway
時間枠：Annually at 1, 2, 3, 4, and 5 years.
|
The number of participants attending through the symptomatic referral pathway will be recorded and compared before and after implementation of the intervention.
|
Annually at 1, 2, 3, 4, and 5 years.
|
|
Economic Burden of Surveillance Pathway
時間枠：Costs will be assessed annually over 5 years and analyzed at 5 year follow-up.
|
A cost analysis will be conducted comparing the standard surveillance pathway with the de-escalated surveillance pathway, including healthcare utilization costs.
|
Costs will be assessed annually over 5 years and analyzed at 5 year follow-up.
|
|
Waiting Time for Newly Diagnosed Breast Cancer Patients
時間枠：Assessed annually at 1, 2, 3, 4, and 5 years.
|
Waiting time will be defined as the time from referral to first outpatient appointment for patients with newly diagnosed breast cancer.
Annual changes in waiting times will be evaluated.
|
Assessed annually at 1, 2, 3, 4, and 5 years.
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
出版物と役立つリンク
研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。
一般刊行物
- General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial. Wattchow D A., Weller DP, Esterman A. et al. British Journal of Cancer (2006) 94, 1116 - 1121
- Patient satisfaction with nurse-led telephone fiollow-up after curative treatment for breast cancer. Kimman M. L. , Bloebaum M. MF, Dirksen C. D, et al. BMC Cancer 2010, 10:174
- Brown L, Payne S, Royle G. Patient initiated follow up of breast cancer. Psychooncology. 2002 Jul-Aug;11(4):346-55. doi: 10.1002/pon.576.
- Follow-up in breast cancer: does routine clinical examination improve outcome? A systemic review of the literature. Montgomery DA, Krupa K, Cooke TG. British Journal of Cancer (2007) 97, 1632 - 1641
- Assessing Mode of Recurrence in Breast Cancer to Identify an Optimised Follow-Up Pathway: 10-Year Institutional Review. Horan J., Reid C., Boland M.R. et al. Ann Surg Oncol 30, 6117-6124 (2023) https://doi.org/10.1245/s10434-023-13885-7
- Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: results from a randomized controlled trial. Grunfeld E., Fitzpatrick R., Mant D. et al. British Journal of General Practice, 1999, 49, 705-710
- 4) A systemic review of the effectiveness of patient-initiated follow-up after cancer. Dretzke J., Chaudri T., Balaji R. et al. Cancer Medicine. 2023;12:19057-19071
- AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. Ditsch N., W.cke A., Untch M., et al. Breast Care 2022;17:403-420
- American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. Runowicz C. D., Leach C. R., PhD, Henry N. L., et al. CA Cancer J Clin 2016;66:43-73.VC 2015 American Cancer Society
- National Cancer Control Programme (NCCP), Draft HSE National Clinical Guideline, Post-treatment follow-up of patients with breast cancer
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2025年12月11日
一次修了 (推定)
2027年12月31日
研究の完了 (推定)
2028年6月1日
試験登録日
最初に提出
2025年12月5日
QC基準を満たした最初の提出物
2026年4月30日
最初の投稿 (実際)
2026年5月7日
学習記録の更新
投稿された最後の更新 (実際)
2026年5月7日
QC基準を満たした最後の更新が送信されました
2026年4月30日
最終確認日
2025年12月1日
詳しくは
本研究に関する用語
その他の研究ID番号
- 25/52
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。